Navicixizumab (Anti-DLL4)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP-305B83; Anti-DLL4 Reference Antibody
Additionnal Information
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400096-100 1x 100 µL
Histone H1 (AE-4), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC941429-100 1x 100 µL
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040003-100 1x 100 µL
CD45RO (UCHL-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 